vs
EXACT SCIENCES CORP（EXAS）与SUN COMMUNITIES INC（SUI）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是SUN COMMUNITIES INC的1.3倍（$878.4M vs $697.2M），SUN COMMUNITIES INC净利率更高（1.7% vs -9.8%，领先11.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs -25.8%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -2.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Sun Communities是一家上市房地产投资信托基金，核心投资品类为预制住宅社区及房车营地物业。截至2025年6月2日，该公司在美国、加拿大、英国三地合计持有500处相关资产的权益，专注于居住及休闲类不动产投资领域。
EXAS vs SUI — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$697.2M
营收增速更快
EXAS
高出48.9%
-25.8%
净利率更高
SUI
高出11.5%
-9.8%
两年增速更快
EXAS
近两年复合增速
-2.1%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $697.2M |
| 净利润 | $-86.0M | $12.1M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.8% | 1.7% |
| 营收同比 | 23.1% | -25.8% |
| 净利润同比 | 90.1% | -96.0% |
| 每股收益（稀释后） | $-0.45 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSUI
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $697.2M | ||
| Q2 25 | $811.1M | $623.5M | ||
| Q1 25 | $706.8M | $470.2M | ||
| Q4 24 | $713.4M | $745.9M | ||
| Q3 24 | $708.7M | $939.9M | ||
| Q2 24 | $699.3M | $864.0M | ||
| Q1 24 | $637.5M | $671.3M |
净利润EXASSUI
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $12.1M | ||
| Q2 25 | $-1.2M | $1.3B | ||
| Q1 25 | $-101.2M | $-41.2M | ||
| Q4 24 | $-864.6M | $-228.4M | ||
| Q3 24 | $-38.2M | $300.5M | ||
| Q2 24 | $-15.8M | $56.7M | ||
| Q1 24 | $-110.2M | $-25.2M |
毛利率EXASSUI
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASSUI
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -16.7% | — |
净利率EXASSUI
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 1.7% | ||
| Q2 25 | -0.1% | 210.8% | ||
| Q1 25 | -14.3% | -8.8% | ||
| Q4 24 | -121.2% | -30.6% | ||
| Q3 24 | -5.4% | 32.0% | ||
| Q2 24 | -2.3% | 6.6% | ||
| Q1 24 | -17.3% | -3.8% |
每股收益（稀释后）EXASSUI
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | $0.07 | ||
| Q2 25 | $-0.01 | $10.02 | ||
| Q1 25 | $-0.54 | $-0.34 | ||
| Q4 24 | $-4.69 | $-1.80 | ||
| Q3 24 | $-0.21 | $2.31 | ||
| Q2 24 | $-0.09 | $0.42 | ||
| Q1 24 | $-0.60 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $542.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $7.0B |
| 总资产 | $5.9B | $12.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSUI
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $542.7M | ||
| Q2 25 | $858.4M | $889.7M | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | $47.4M | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | — |
总债务EXASSUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.4B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXASSUI
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $7.0B | ||
| Q2 25 | $2.5B | $7.4B | ||
| Q1 25 | $2.4B | $6.9B | ||
| Q4 24 | $2.4B | $7.1B | ||
| Q3 24 | $3.2B | $7.5B | ||
| Q2 24 | $3.2B | $6.9B | ||
| Q1 24 | $3.1B | $6.9B |
总资产EXASSUI
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $12.8B | ||
| Q2 25 | $5.8B | $13.4B | ||
| Q1 25 | $5.7B | $16.5B | ||
| Q4 24 | $5.9B | $16.5B | ||
| Q3 24 | $6.7B | $17.1B | ||
| Q2 24 | $6.7B | $17.0B | ||
| Q1 24 | $6.4B | $17.1B |
负债/权益比EXASSUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $197.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 16.35× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASSUI
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $197.8M | ||
| Q2 25 | $89.0M | $256.0M | ||
| Q1 25 | $30.8M | $243.9M | ||
| Q4 24 | $47.1M | $118.0M | ||
| Q3 24 | $138.7M | $189.2M | ||
| Q2 24 | $107.1M | $311.3M | ||
| Q1 24 | $-82.3M | $242.5M |
自由现金流EXASSUI
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASSUI
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASSUI
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASSUI
| Q4 25 | — | — | ||
| Q3 25 | — | 16.35× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | 5.49× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SUI
暂无分部数据
